Recent Advances in Pathology & Laboratory Medicine
Volume 10, Issue 1&2 - 2024, Pg. No. 7-10
Peer Reviewed & Open Access Journal

Medical Report

"The Race Against a Silent Killer" World health organization report on Hypertension: 2023

Harshita Thappar[1], Harshdeep Singh[2], Navneet Saini[3]

[1,2]Student, Adesh Institute of Medical Sciences and Research, Punjab, India.
[3]Associate Professor, Department of Physiology, Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, India.
DOI: https://doi.org/10.24321/2454.8642.202403

I N F O

Corresponding Author:
Navneet Saini, Department of Physiology, Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, India.
E-mail Id:
drsaininavneet@yahoo.com
Orcid Id:
https://orcid.org/0000-0002-1142-0604
How to cite this article:
Thappar H, Singh H, Saini N. "The Race Against a Silent Killer" World health organization report on Hypertension: 2023. Rec Adv Path Lab Med. 2024;10(1&2):7-10.

Date of Submission: 2024-01-20
Date of Acceptance: 2024-03-15

A B S T R A C T

The World Health Organization's Global Report on Hypertension: The Race Against a Silent Killer provides a comprehensive analysis of the global burden of hypertension. The report highlights that hypertension affects one in three adults worldwide, with the number of individuals living with the condition doubling from 650 million in 1990 to 1.3 billion in 2019. Alarmingly, approximately 46% of adults with hypertension are unaware of their condition, and about 80% are not receiving adequate treatment. The report underscores the significant health risks associated with uncontrolled hypertension, including heart attacks, strokes, kidney damage, and premature death. It also emphasizes the economic impact, noting substantial losses for communities and countries. The report advocates for the implementation of effective hypertension management strategies, such as the WHO HEARTS technical package, and highlights the potential to prevent 76 million deaths between 2023 and 2050 through improved treatment coverage.

Keywords: Hypertension, Global burden, Cardiovascular diseases , Public health

Introduction

Hypertension, commonly referred to as high blood pressure, is a major risk factor for cardiovascular diseases (CVDs), including heart attack, stroke, and kidney failure. Recognized as a silent killer due to its asymptomatic progression, hypertension affects a significant proportion of the global population. The World Health Organization (WHO) Global Report on Hypertension (2023) highlights the alarming rise in hypertension prevalence worldwide, its associated health burden, and treatment strategies to combat this public health crisis.[1]

Aim of the Report

The WHO Global Report on Hypertension aims to provide a comprehensive overview of the global and regional burden of hypertension, identify gaps in prevention and treatment, and propose evidence-based strategies to address these challenges. By leveraging data from 1990 to 2019 on individuals aged 30 to 79 years, the report seeks to support countries in scaling up interventions for hypertension prevention, early detection, and effective management.

Background

Hypertension has been a persistent health challenge for decades. The global prevalence of hypertension in adults aged 30 to 79 years has risen steadily, driven by lifestyle changes, dietary habits, and aging populations. Despite the availability of effective treatments, a significant proportion of individuals remain undiagnosed or inadequately managed. This has led to preventable morbidity and mortality due to CVDs. Recognizing these challenges, the

WHO has prioritized hypertension in its global health agenda, aligning efforts with the Sustainable Development Goals (SDGs) to reduce premature mortality from non-communicable diseases (NCDs) by one-third by 2030.[1,2]

Data Source and Methodology

The WHO report employs a robust methodology to estimate the global burden of hypertension and evaluate treatment strategies. The analysis draws on population-representative studies conducted from 1990 to 2019. The studies include direct blood pressure measurements and information on antihypertensive treatment. Data were collected on individuals aged 30 to 79 years. The analysis covers diverse geographic regions and income groups to ensure representativeness.

The report draws on a rich dataset comprising studies that utilized direct blood pressure measurements, ensuring the reliability and accuracy of the findings. These studies also incorporated detailed information on the use of antihypertensive treatments, providing valuable insights into the effectiveness of current interventions. The focus on individuals aged 30 to 79 years aligns with the age group most at risk for developing hypertension, capturing the key demographic for targeted prevention and management strategies.

To ensure representativeness, the WHO report incorporates data from diverse geographic regions and income groups. This inclusivity is crucial for understanding the global burden of hypertension, as the prevalence and treatment of the condition are influenced by socioeconomic factors, healthcare infrastructure, and cultural practices. By including populations from low-, middle-, and high-income countries, the report provides a nuanced view of disparities and commonalities in hypertension prevalence and management worldwide.

Insights and Implications

The analysis provides critical insights into how the burden of hypertension has evolved over time and across regions. It highlights patterns in prevalence, treatment coverage, and effectiveness, enabling policymakers and healthcare professionals to identify areas requiring urgent attention. For instance, the report underscores disparities in treatment access and outcomes, particularly in low-income regions, where healthcare resources are often limited. These findings emphasize the need for targeted interventions to improve access to effective antihypertensive therapies in underserved populations.[3,4]

Furthermore, the report evaluates the effectiveness of various antihypertensive treatment strategies, offering evidence-based recommendations for optimizing care. By analysing data over a 30-year period, the WHO can assess trends in treatment adherence, the impact of innovations in medical therapies, and the role of healthcare systems in supporting patients with hypertension. This long-term perspective is invaluable for designing sustainable and scalable interventions to reduce the global burden of hypertension.[5,6]

Contribution to Global Health

The WHO report is an essential resource for shaping global health policies and strategies aimed at combating hypertension. Its robust methodology ensures that the findings are credible and actionable, providing a solid foundation for international efforts to reduce morbidity and mortality associated with this condition. The focus on population-representative data underscores the importance of equity in healthcare, as the report sheds light on the unique challenges faced by different demographic and socioeconomic groups.[7]

By offering a comprehensive assessment of the global burden of hypertension and evaluating treatment strategies, the WHO report equips stakeholders with the knowledge needed to implement effective, evidence-based interventions. Its emphasis on inclusivity and methodological rigor sets a high standard for future research and reinforces the importance of addressing hypertension as a priority in global public health.[8]

Data Analysis

- Hypertension was defined as systolic blood pressure (SBP) ≥140 mmHg, diastolic blood pressure (DBP) ≥90 mmHg, or current use of antihypertensive medication. Trends in hypertension prevalence, treatment coverage, and control rates were analyzed.[7]
- In 2019, approximately 1.28 billion adults aged 30 to 79 years were living with hypertension globally.[8]
- The prevalence was higher in low- and middle-income countries (LMICs) compared to high-income countries (HICs).[9]
- While awareness of hypertension has improved over the decades, treatment rates remain suboptimal, especially in LMICs.[9]
- Among those treated, only a fraction achieved adequate blood pressure control.
- The highest prevalence rates were observed in Sub-Saharan Africa and South Asia.
- High-income regions like North America and Europe reported better treatment and control rates but still faced challenges in addressing undiagnosed cases.[10]

Treatment Strategies: The WHO report emphasizes a comprehensive approach to tackling hypertension, focusing on evidence-based treatment strategies to address the global burden of the condition. These strategies aim to reduce the prevalence of hypertension and improve health outcomes by targeting prevention, early detection, effective

ISSN: 2454-8642
DOI: https://doi.org/10.24321/2454.8642.202403

treatment, and long-term management.[11] Below are the key strategies highlighted in the report:

Improving Access to Antihypertensive Medications[6,7]

Ensuring the availability and affordability of essential antihypertensive drugs is a cornerstone of the WHO's treatment strategy. The report underscores the need for governments and healthcare systems to strengthen supply chains and minimize financial barriers to accessing medications. This is particularly critical in low- and middle-income countries, where out-of-pocket costs often limit patient adherence. By promoting the use of cost-effective, generic medications, the WHO advocates for scalable solutions that can benefit broader populations without straining healthcare budgets.

Simplified and Standardized Treatment Protocols[11,12]

The report highlights the importance of adopting simplified and standardized treatment protocols to enhance the management of hypertension across diverse healthcare settings. Simplified protocols involve using fixed-dose combination therapies and standard regimens that reduce complexity for healthcare providers and patients. These protocols improve adherence to treatment, streamline care delivery, and enable more healthcare workers to provide quality care even in resource-limited environments.

Integration of Hypertension Care into Primary Healthcare[3,4]

Integrating hypertension diagnosis and treatment into primary healthcare services is a pivotal recommendation. The report emphasizes that primary care providers should be trained to routinely screen for hypertension and manage uncomplicated cases. This strategy ensures early detection and timely intervention, especially in rural and underserved areas where access to specialized care is limited. Primary care integration also supports continuity of care, fostering long-term management of hypertension to prevent complications such as heart disease and stroke.

Strengthening Health System Capacity[2,3]

A well-functioning health system is essential for effective hypertension management. The report advocates for investments in healthcare infrastructure, workforce training, and digital tools to support hypertension care. Telemedicine and mobile health technologies, for instance, are highlighted as valuable tools for remote monitoring, patient education, and improving adherence to treatment plans. Strengthening health system capacity also involves building robust referral networks to ensure that patients with resistant hypertension or complex needs can access specialized care.

Promoting Patient-Cantered Care[6,8]

Patient-centred care is another key strategy emphasized in the WHO report. This approach involves tailoring treatment plans to the unique needs, preferences, and circumstances of each patient. Counselling on the importance of lifestyle modifications, medication adherence, and regular follow-ups are integral to this strategy. Additionally, engaging patients in shared decision-making empowers them to take an active role in their care, improving long-term outcomes.

Lifestyle Interventions as Adjuncts to Pharmacotherapy[9,12]

The WHO underscores the critical role of lifestyle interventions in complementing pharmacological treatment. Key recommendations include dietary modifications such as reducing salt intake, increasing consumption of fruits and vegetables, and adopting the DASH (Dietary Approaches to Stop Hypertension) diet. Physical activity, weight management, smoking cessation, and reducing alcohol consumption are also advocated as effective measures to lower blood pressure and enhance overall cardiovascular health. Public health campaigns and community-based programs are encouraged to support widespread adoption of these practices.

Addressing Disparities in Hypertension Care[4,7]

The report stresses the need to reduce disparities in hypertension care by prioritizing equity in healthcare access and outcomes. This involves targeting vulnerable populations, such as those in low-income regions, women, and older adults, who are disproportionately affected by hypertension and its complications. Tailored strategies to improve awareness, access, and adherence to treatment among these groups are vital to achieving equitable health outcomes.

Monitoring and Evaluating Treatment Programs[2,8]

Continuous monitoring and evaluation of hypertension treatment programs are essential to ensure their effectiveness and scalability. The WHO advocates for the use of data-driven approaches to track progress, identify gaps, and refine interventions. This includes leveraging health information systems to collect and analyze data on treatment adherence, blood pressure control rates, and the impact of interventions on population health.

Collaborative Efforts Across Sectors[1,9]

The WHO emphasizes the importance of multisectoral collaboration in addressing hypertension. Partnerships between governments, non-governmental organizations, private healthcare providers, and community groups are necessary to implement large-scale interventions. Policies that support healthy environments, such as reducing

ISSN: 2454-8642
DOI: https://doi.org/10.24321/2454.8642.202403

sodium in processed foods and creating spaces for physical activity, complement clinical strategies and address the root causes of hypertension.

Conclusion

The WHO Global Report on Hypertension (2023) underscores the urgent need for coordinated global action to address the growing burden of hypertension. The findings highlight critical gaps in awareness, treatment, and control that must be bridged to prevent CVD-related morbidity and mortality. By implementing the recommended strategies, countries can make significant progress toward achieving global health targets and improving the quality of life for millions of individuals.

References

1. World Health Organization. Global Report on Hypertension 2023. Geneva: WHO; 2023.
2. World Health Organization. Hypertension: Silent killer, global public health crisis. Geneva: WHO; 2023.
3. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and treatment from 1990 to 2019: A pooled analysis of population-based studies. Lancet. 2023;401(10395):123-133.
4. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet. 2022;360(9344):123-133.[Google Scholar]
5. World Health Organization. Noncommunicable Diseases Progress Monitor 2023. Geneva: WHO; 2023.
6. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2023;289(19):2560-72.[Google Scholar]
7. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global burden of hypertension and trends from 1990 to 2023: A systematic analysis. Lancet. 2023;388(10053):1073-1090.[Google Scholar]
8. World Health Organization. WHO Global NCD Action Plan 2013–2023. Geneva: WHO; 2023.
9. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2022;16(4):223-237. [Google Scholar]
10. Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021;18(11):785-802 [Google Scholar]
11. World Health Organization. Sodium Intake for Adults and Children: Guideline. Geneva: WHO; 2023.
12. Campbell NRC, Lackland DT, Niebylski ML, Orias M, Redburn KA. Population dietary sodium reduction: The state of the science. J Clin Hypertens. 2023;15(11):801-805.

ISSN: 2454-8642
DOI: https://doi.org/10.24321/2454.8642.202403